Groups Urge Fed. Circ. To Rethink Novo Nordisk Win

Law360, New York (June 3, 2010, 7:37 PM EDT) -- Amicus briefs calling for review of the U.S. Court of Appeals for the Federal Circuit's ruling for Novo Nordisk A/S in a fight over its diabetes drug Prandin are continuing to pile up, with the Generic Pharmaceutical Association on Thursday joining the chorus of consumers and generics makers arguing that the decision makes it easier for Big Pharma to keep cheap drugs off shelves.

The industry group's brief follows similar briefs filed May 28 by Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA Inc., the Consumer Federation of...
To view the full article, register now.